{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:50:18Z","timestamp":1792363818119,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Digital health technologies show promise for improving the measurement of Parkinson\u2019s disease in clinical research and trials. However, it is not clear whether digital measures demonstrate enhanced sensitivity to disease progression compared to traditional measurement approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To this end, we develop a wearable sensor-based digital algorithm for deriving features of upper and lower-body bradykinesia and evaluate the sensitivity of digital measures to 1-year longitudinal progression using data from the WATCH-PD study, a multicenter, observational digital assessment study in participants with early, untreated Parkinson\u2019s disease. In total, 82 early, untreated Parkinson\u2019s disease participants and 50 age-matched controls were recruited and took part in a variety of motor tasks over the course of a 12-month period while wearing body-worn inertial sensors. We establish clinical validity of sensor-based digital measures by investigating convergent validity with appropriate clinical constructs, known groups validity by distinguishing patients from healthy volunteers, and test-retest reliability by comparing measurements between visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We demonstrate clinical validity of the digital measures, and importantly, superior sensitivity of digital measures for distinguishing 1-year longitudinal change in early-stage PD relative to corresponding clinical constructs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results demonstrate the potential of digital health technologies to enhance sensitivity to disease progression relative to existing measurement standards and may constitute the basis for use as drug development tools in clinical research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-024-00481-3","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:01:51Z","timestamp":1710504111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Improved measurement of disease progression in people living with early Parkinson\u2019s disease using digital health technologies"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9954-7003","authenticated-orcid":false,"given":"Matthew D.","family":"Czech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Badley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6786-2658","authenticated-orcid":false,"given":"Michelle","family":"Crouthamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tairmae","family":"Kangarloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-1248","authenticated-orcid":false,"given":"E. Ray","family":"Dorsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3320-4053","authenticated-orcid":false,"given":"Josh D.","family":"Cosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"481_CR1","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.3233\/JPD-202428","volume":"11","author":"D Stephenson","year":"2021","unstructured":"Stephenson, D., Badawy, R., Mathur, S., Tome, M. & Rochester, L. Digital progression biomarkers as novel endpoints in clinical trials: a multistakeholder perspective. J. Parkinsons Dis. 11, S103\u2013S109 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"481_CR2","doi-asserted-by":"crossref","unstructured":"Rees, R. N., Acharya, A. P., Schrag, A. & Noyce, A. J. An early diagnosis is not the same as a timely diagnosis of Parkinson\u2019s disease. F1000Research 7, F1000 Faculty Rev-1106 (2018).","DOI":"10.12688\/f1000research.14528.1"},{"key":"481_CR3","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/mds.27790","volume":"34","author":"LJW Evers","year":"2019","unstructured":"Evers, L. J. W., Krijthe, J. H., Meinders, M. J., Bloem, B. R. & Heskes, T. M. Measuring Parkinson\u2019s disease over time: the real-world within-subject reliability of the MDS-UPDRS. Mov. Disord. 34, 1480\u20131487 (2019).","journal-title":"Mov. Disord."},{"key":"481_CR4","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00415-019-09348-3","volume":"266","author":"A Regnault","year":"2019","unstructured":"Regnault, A. et al. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson\u2019s disease? Learnings from the Parkinson\u2019s progression marker initiative cohort. J. Neurol. 266, 1927\u20131936 (2019).","journal-title":"J. Neurol."},{"key":"481_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fnins.2018.00202","volume":"12","author":"JJ FitzGerald","year":"2018","unstructured":"FitzGerald, J. J., Lu, Z., Jareonsettasin, P. & Antoniades, C. A. Quantifying motor impairment in movement disorders. Front. Neurosci. 12, 202 (2018).","journal-title":"Front. Neurosci."},{"key":"481_CR6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fnins.2017.00555","volume":"11","author":"E Rovini","year":"2017","unstructured":"Rovini, E., Maremmani, C. & Cavallo, F. How wearable sensors can support Parkinson\u2019s disease diagnosis and treatment: a systematic review. Front. Neurosci. 11, 555 (2017).","journal-title":"Front. Neurosci."},{"key":"481_CR7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/mds.26718","volume":"31","author":"S Del Din","year":"2016","unstructured":"Del Din, S., Godfrey, A., Mazz\u00e0, C., Lord, S. & Rochester, L. Free-living monitoring of Parkinson\u2019s disease: lessons from the field. Mov. Disord. 31, 1293\u20131313 (2016).","journal-title":"Mov. Disord."},{"key":"481_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-022-00568-y","volume":"5","author":"AS Chandrabhatla","year":"2022","unstructured":"Chandrabhatla, A. S., Pomeraniec, I. J. & Ksendzovsky, A. Co-evolution of machine learning and digital technologies to improve monitoring of Parkinson\u2019s disease motor symptoms. Npj Digital Med. 5, 1\u201318 (2022).","journal-title":"Npj Digital Med."},{"key":"481_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29382-6","volume":"13","author":"G Oyama","year":"2023","unstructured":"Oyama, G. et al. Analytical and clinical validity of wearable, multi-sensor technology for assessment of motor function in patients with Parkinson\u2019s disease in Japan. Sci. Rep. 13, 3600 (2023).","journal-title":"Sci. Rep."},{"key":"481_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-021-00513-5","volume":"4","author":"A Polhemus","year":"2021","unstructured":"Polhemus, A. et al. Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes. Npj Digital Med. 4, 1\u201314 (2021).","journal-title":"Npj Digital Med."},{"key":"481_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-023-00497-x","volume":"9","author":"JL Adams","year":"2023","unstructured":"Adams, J. L. et al. Using a smartwatch and smartphone to assess early Parkinson\u2019s disease in the WATCH-PD study. Npj Parkinsons Dis. 9, 1\u201310 (2023).","journal-title":"Npj Parkinsons Dis."},{"key":"481_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15874-4","volume":"12","author":"F Lipsmeier","year":"2022","unstructured":"Lipsmeier, F. et al. Reliability and validity of the Roche PD mobile application for remote monitoring of early Parkinson\u2019s disease. Sci. Rep. 12, 12081 (2022).","journal-title":"Sci. Rep."},{"key":"481_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41746-022-00607-8","volume":"5","author":"M Burq","year":"2022","unstructured":"Burq, M. et al. Virtual exam for Parkinson\u2019s disease enables frequent and reliable remote measurements of motor function. NPJ Digital Med. 5, 65 (2022).","journal-title":"NPJ Digital Med."},{"key":"481_CR14","doi-asserted-by":"publisher","first-page":"e16415","DOI":"10.1016\/j.heliyon.2023.e16415","volume":"9","author":"MA Brzezicki","year":"2023","unstructured":"Brzezicki, M. A., Conway, N., Sotirakis, C., FitzGerald, J. J. & Antoniades, C. A. Antiparkinsonian medication masks motor signal progression in de novo patients. Heliyon 9, e16415 (2023).","journal-title":"Heliyon"},{"key":"481_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-021-00227-1","volume":"7","author":"G Di Lazzaro","year":"2021","unstructured":"Di Lazzaro, G. et al. Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson\u2019s disease cohort. Npj Parkinsons Dis. 7, 1\u20137 (2021).","journal-title":"Npj Parkinsons Dis."},{"key":"481_CR16","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.3390\/s20205920","volume":"20","author":"M Viceconti","year":"2020","unstructured":"Viceconti, M. et al. Toward a regulatory qualification of real-world mobility performance biomarkers in Parkinson\u2019s patients using digital mobility outcomes. Sensors 20, 5920 (2020).","journal-title":"Sensors"},{"key":"481_CR17","doi-asserted-by":"publisher","first-page":"996903","DOI":"10.3389\/fmed.2022.996903","volume":"9","author":"M Viceconti","year":"2022","unstructured":"Viceconti, M. et al. On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: a regulatory perspective. Front. Med. 9, 996903 (2022).","journal-title":"Front. Med."},{"key":"481_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-020-0260-4","volume":"3","author":"JC Goldsack","year":"2020","unstructured":"Goldsack, J. C. et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). Npj Digital Med. 3, 1\u201315 (2020).","journal-title":"Npj Digital Med."},{"key":"481_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000514730","volume":"5","author":"JC Goldsack","year":"2021","unstructured":"Goldsack, J. C., Dowling, A. V., Samuelson, D., Patrick-Lake, B. & Clay, I. Evaluation, acceptance, and qualification of digital measures: from proof of concept to endpoint. Digit. Biomark. 5, 53\u201364 (2021).","journal-title":"Digit. Biomark."},{"key":"481_CR20","doi-asserted-by":"publisher","first-page":"7876","DOI":"10.3390\/s21237876","volume":"21","author":"JGV Habets","year":"2021","unstructured":"Habets, J. G. V. et al. Rapid dynamic naturalistic monitoring of bradykinesia in Parkinson\u2019s disease using a wrist-worn accelerometer. Sensors 21, 7876 (2021).","journal-title":"Sensors"},{"key":"481_CR21","first-page":"1","volume":"8","author":"A Rodriguez-Molinero","year":"2017","unstructured":"Rodriguez-Molinero, A. et al. Analysis of correlation between an accelerometer-based algorithm for detecting Parkinsonian gait and UPDRS subscales. Front. Neurol. 8, 1\u20136 (2017).","journal-title":"Front. Neurol."},{"key":"481_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1109\/TBME.2017.2697764","volume":"65","author":"CL Pulliam","year":"2018","unstructured":"Pulliam, C. L. et al. Continuous assessment of levodopa response in Parkinson\u2019s disease using wearable motion sensors. IEEE Trans. Biomed. Eng. 65, 159\u2013164 (2018).","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"481_CR23","doi-asserted-by":"publisher","unstructured":"Daneault, J. F. et al. Estimating bradykinesia in Parkinson\u2019s disease with a minimum number of wearable sensors. in Proc. 2017 IEEE 2nd International Conference on Connected Health: Applications, Systems and Engineering Technologies CHASE 2017 264\u2013265 https:\/\/doi.org\/10.1109\/CHASE.2017.94 (2017).","DOI":"10.1109\/CHASE.2017.94"},{"key":"481_CR24","doi-asserted-by":"publisher","first-page":"e0124522","DOI":"10.1371\/journal.pone.0124522","volume":"10","author":"MK Horne","year":"2015","unstructured":"Horne, M. K., McGregor, S. & Bergquist, F. An objective fluctuation score for Parkinson\u2019s disease. PLoS ONE 10, e0124522 (2015).","journal-title":"PLoS ONE"},{"key":"481_CR25","doi-asserted-by":"publisher","first-page":"21329","DOI":"10.3390\/s141121329","volume":"14","author":"AT Tzallas","year":"2014","unstructured":"Tzallas, A. T. et al. PERFORM: a system for monitoring, assessment and management of patients with Parkinson\u2019s disease. Sensors 14, 21329\u201321357 (2014).","journal-title":"Sensors"},{"key":"481_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/JPD-2012-11071","volume":"2","author":"RI Griffiths","year":"2012","unstructured":"Griffiths, R. I. et al. Automated assessment of bradykinesia and dyskinesia in Parkinson\u2019s disease. J. Parkinsons Dis 2, 47\u201355 (2012).","journal-title":"J. Parkinsons Dis"},{"key":"481_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1109\/TBME.2006.886670","volume":"54","author":"A Salarian","year":"2007","unstructured":"Salarian, A. et al. Quantification of tremor and bradykinesia in Parkinson\u2019s disease using a novel ambulatory monitoring system. IEEE Trans. Biomed. Eng. 54, 313\u2013322 (2007).","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"481_CR28","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1007\/s10439-017-1908-3","volume":"45","author":"AG Rabelo","year":"2017","unstructured":"Rabelo, A. G. et al. Objective assessment of bradykinesia estimated from the wrist extension in older adults and patients with Parkinson\u2019s disease. Ann. Biomed. Eng. 45, 2614\u20132625 (2017).","journal-title":"Ann. Biomed. Eng."},{"key":"481_CR29","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1109\/TBME.2015.2480242","volume":"63","author":"O Martinez-Manzanera","year":"2016","unstructured":"Martinez-Manzanera, O. et al. A method for automatic and objective scoring of bradykinesia using orientation sensors and classification algorithms. IEEE Trans. Biomed. Eng. 63, 1016\u20131024 (2016).","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"481_CR30","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/mds.23740","volume":"26","author":"DA Heldman","year":"2011","unstructured":"Heldman, D. A. et al. The modified bradykinesia rating scale for Parkinson\u2019s disease: reliability and comparison with kinematic measures. Mov. Disord. 26, 1859\u20131863 (2011).","journal-title":"Mov. Disord."},{"key":"481_CR31","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1109\/TBME.2010.2049573","volume":"57","author":"DGM Zwartjes","year":"2010","unstructured":"Zwartjes, D. G. M., Heida, T., van Vugt, J. P. P., Geelen, J. A. G. & Veltink, P. H. Ambulatory monitoring of activities and motor symptoms in Parkinson\u2019s disease. IEEE Trans. Biomed. Eng. 57, 2778\u20132786 (2010).","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"481_CR32","doi-asserted-by":"publisher","first-page":"e1008833","DOI":"10.1371\/journal.pcbi.1008833","volume":"17","author":"C Stamate","year":"2021","unstructured":"Stamate, C., Pons, J. S., Weston, D. & Roussos, G. PDKit: a data science toolkit for the digital assessment of Parkinson\u2019s disease. PLoS Comput. Biol. 17, e1008833 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"481_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-019-0217-7","volume":"3","author":"N Mahadevan","year":"2020","unstructured":"Mahadevan, N. et al. Development of digital biomarkers for resting tremor and bradykinesia using a wrist-worn wearable device. Npj Digital Med. 3, 1\u201312 (2020).","journal-title":"Npj Digital Med."},{"key":"481_CR34","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acn3.644","volume":"5","author":"K Marek","year":"2018","unstructured":"Marek, K. et al. The Parkinson\u2019s progression markers initiative (PPMI)\u2014establishing a PD biomarker cohort. Ann. Clin. Transl. Neurol. 5, 1460\u20131477 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"481_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1586\/17434440.2016.1153421","volume":"13","author":"M Mancini","year":"2016","unstructured":"Mancini, M. & Horak, F. B. Potential of APDM Mobility Lab for the monitoring of the progression of Parkinson\u2019s disease. Expert Rev. Med. Devices 13, 455\u2013462 (2016).","journal-title":"Expert Rev. Med. Devices"},{"key":"481_CR36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1037\/1040-3590.6.4.284","volume":"6","author":"DV Cicchetti","year":"1994","unstructured":"Cicchetti, D. V. Guidlines, criteria, and rules of thumb for evalauting normed and standardized assessment instruments in psychology. Psychol. Assess. 6, 284\u2013290 (1994).","journal-title":"Psychol. Assess."},{"key":"481_CR37","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2017)."},{"key":"481_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mdc3.12553","volume":"5","author":"SK Holden","year":"2018","unstructured":"Holden, S. K., Finseth, T., Sillau, S. H. & Berman, B. D. Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson\u2019s progression markers initiative cohort. Mov. Disord. Clin. Pract. 5, 47\u201353 (2018).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"481_CR39","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1093\/brain\/aws093","volume":"135","author":"RB Postuma","year":"2012","unstructured":"Postuma, R. B., Lang, A. E., Gagnon, J. F., Pelletier, A. & Montplaisir, J. Y. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 135, 1860\u20131870 (2012).","journal-title":"Brain"},{"key":"481_CR40","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/mds.10011","volume":"17","author":"A Siderowf","year":"2002","unstructured":"Siderowf, A. et al. Test\u2013retest reliability of the unified Parkinson\u2019s disease rating scale in patients with early Parkinson\u2019s disease: results from a multicenter clinical trial. Mov. Disord. 17, 758\u2013763 (2002).","journal-title":"Mov. Disord."},{"key":"481_CR41","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/brain\/124.11.2131","volume":"124","author":"A Berardelli","year":"2001","unstructured":"Berardelli, A., Rothwell, J. C., Thompson, P. D. & Hallett, M. Pathophysiology of bradykinesia in Parkinson\u2019s disease. Brain 124, 2131\u20132146 (2001).","journal-title":"Brain"},{"key":"481_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-023-00790-2","volume":"6","author":"S Colloud","year":"2023","unstructured":"Colloud, S. et al. Evolving regulatory perspectives on digital health technologies for medicinal product development. Npj Digital Med. 6, 1\u201311 (2023).","journal-title":"Npj Digital Med."},{"key":"481_CR43","unstructured":"Holmstrom, L. How is the orientation of an Opal estimated? Product Support And Information. https:\/\/support.apdm.com\/hc\/en-us\/articles\/115000390803-How-is-the-orientation-of-an-Opal-estimated- (2021)."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00481-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00481-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00481-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:10:28Z","timestamp":1710504628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00481-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1038\/s43856-024-00481-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3235574\/v1","asserted-by":"object"}]},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"10 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: M.D.C., L.Y., J.S., M.C., and J.D.C. are employees of and own stock in AbbVie Pharmaceuticals. J.L.A. has received compensation for consulting services from VisualDx and the Huntington Study Group; and research support from Biogen, Biosensics, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health\/National Institute of Neurological Disorders and Stroke, NeuroNext Network, and Safra Foundation. T.K. is an employee of and owns stock in Takeda Pharmaceuticals, Inc. D.B. was an employee of AbbVie Pharmaceuticals during the time he contributed to this research article. He has no conflicts or interests at the present time. E.R.D. has received compensation for consulting services from Abbott, Abbvie, Acadia, Acorda, Bial-Biotech Investments, Inc., Biogen, Boehringer Ingelheim, California Pacific Medical Center, Caraway Therapeutics, CuraSen Therapeutics, Denali Therapeutics, Eli Lilly, Genentech\/Roche, Grand Rounds, Huntington Study Group, Informa Pharma Consulting, Karger Publications, LifeSciences Consultants, MCM Education, Mediflix, Medopad, Medrhythms, Merck, Michael J. Fox Foundation, NACCME, Neurocrine, NeuroDerm, NIH, Novartis, Origent Data Sciences, Otsuka, Physician\u2019s Education Resource, Praxis, PRIME Education, Roach, Brown, McCarthy & Gruber, Sanofi, Seminal Healthcare, Spark, Springer Healthcare, Sunovion Pharma, Theravance, Voyager and WebMD; research support from Biosensics, Burroughs Wellcome Fund, CuraSen, Greater Rochester Health Foundation, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health, Patient-Centered Outcomes Research Institute, Pfizer, PhotoPharmics, Safra Foundation, and Wave Life Sciences; editorial services for Karger Publications; stock in Included Health and in Mediflix, and ownership interests in SemCap.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}